Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
*Swallow the tablet as it is without breaking, crushing, or chewing
Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic peptide) receptors, triggering a dual metabolic response
ATTAIN-2 (NCT05872620) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes
They looked at a 5 year cohort study
US$ 20.09
US$ 20.81
US$ 24.41
US$ 23.39
US$ 26.25
US$ 23.95
US$ 22.69
